Silvia Hofer

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Undifferentiated sarcoma arising in the brain, 23 years after curative treatment of an ependymoma
    Silvia Hofer
    Department of Oncology, University Hospital Zurich, Ramistrasse 100, Zurich, 8091, Switzerland
    J Neurooncol 72:239. 2005
  2. doi Early metabolic responses in temozolomide treated low-grade glioma patients
    Matthias Wyss
    PET Center, Division of Nuclear Medicine, University Hospital, Zurich, Switzerland
    J Neurooncol 95:87-93. 2009
  3. ncbi Gefitinib concentrations in human glioblastoma tissue
    Silvia Hofer
    Medical Oncology, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland
    J Neurooncol 82:175-6. 2007
  4. doi Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial
    Christoph Oehler
    Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
    Oncology 83:1-9. 2012
  5. doi Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
    Silvia Hofer
    Department of Oncology, University Hospital Zurich, Switzerland
    Acta Oncol 50:630-5. 2011
  6. doi Molecular markers in gliomas: impact for the clinician
    Silvia Hofer
    Department of Oncology, University Hospital Zurich, Zurich, Switzerland
    Target Oncol 5:201-10. 2010
  7. doi A specific miRNA signature in the peripheral blood of glioblastoma patients
    Patrick Roth
    Department of Neurology, University Hospital Zurich, Zurich, Switzerland
    J Neurochem 118:449-57. 2011
  8. ncbi Treatment of breast cancer brain metastases
    Silvia Hofer
    Department of Oncology, University Hospital, Raemistrasse 100, 8091 Zurich, Switzerland
    Eur J Pharmacol 717:84-7. 2013
  9. pmc Molecular biology of high-grade gliomas: what should the clinician know?
    Silvia Hofer
    Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland
    Chin J Cancer 33:4-7. 2014
  10. ncbi Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake
    Matthias T Wyss
    PET Center, Division of Nuclear Medicine, University Hospital, Zurich, Switzerland
    J Nucl Med 48:1047-52. 2007

Collaborators

Detail Information

Publications18

  1. ncbi Undifferentiated sarcoma arising in the brain, 23 years after curative treatment of an ependymoma
    Silvia Hofer
    Department of Oncology, University Hospital Zurich, Ramistrasse 100, Zurich, 8091, Switzerland
    J Neurooncol 72:239. 2005
  2. doi Early metabolic responses in temozolomide treated low-grade glioma patients
    Matthias Wyss
    PET Center, Division of Nuclear Medicine, University Hospital, Zurich, Switzerland
    J Neurooncol 95:87-93. 2009
    ..Response assessment based on MR only has to be reconsidered. The time window obtained from PET may assist for individual treatment decisions in LGG patients...
  3. ncbi Gefitinib concentrations in human glioblastoma tissue
    Silvia Hofer
    Medical Oncology, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland
    J Neurooncol 82:175-6. 2007
  4. doi Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial
    Christoph Oehler
    Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
    Oncology 83:1-9. 2012
    ..Patupilone (EPO906) is a novel natural microtubule-stabilizing cytotoxic agent that crosses the blood-brain barrier and has been found to have preclinical activity in glioma models...
  5. doi Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
    Silvia Hofer
    Department of Oncology, University Hospital Zurich, Switzerland
    Acta Oncol 50:630-5. 2011
    ..High levels of vascular endothelial growth factor (VEGF) expressed in HGG make the anti-VEGF monoclonal antibody bevacizumab (BEV) of particular interest...
  6. doi Molecular markers in gliomas: impact for the clinician
    Silvia Hofer
    Department of Oncology, University Hospital Zurich, Zurich, Switzerland
    Target Oncol 5:201-10. 2010
    ..The most recently discovered IDH mutation is a striking example of a rapid implementation of a molecular marker for prognostication into common clinical use...
  7. doi A specific miRNA signature in the peripheral blood of glioblastoma patients
    Patrick Roth
    Department of Neurology, University Hospital Zurich, Zurich, Switzerland
    J Neurochem 118:449-57. 2011
    ..In summary, our proof-of-concept study demonstrates that blood-derived glioblastoma-associated characteristic miRNA fingerprints may be suitable biomarkers and warrant further exploration...
  8. ncbi Treatment of breast cancer brain metastases
    Silvia Hofer
    Department of Oncology, University Hospital, Raemistrasse 100, 8091 Zurich, Switzerland
    Eur J Pharmacol 717:84-7. 2013
    ..Asymptomatic brain metastases may be first approached with a systemic treatment to which the primary tumor is considered to be sensitive. ..
  9. pmc Molecular biology of high-grade gliomas: what should the clinician know?
    Silvia Hofer
    Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland
    Chin J Cancer 33:4-7. 2014
    ..This article aims to summarize current knowledge on the molecular biology of high-grade gliomas relevant to daily practice. ..
  10. ncbi Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake
    Matthias T Wyss
    PET Center, Division of Nuclear Medicine, University Hospital, Zurich, Switzerland
    J Nucl Med 48:1047-52. 2007
    ..We used PET with (18)F-fluoro-ethyl-l-tyrosine (FET) to measure the spatial distribution of the amino acid carrier, which is located at the brain capillaries, and (15)O-H(2)O to measure tumor CBF...
  11. ncbi Gefitinib accumulation in glioblastoma tissue
    Silvia Hofer
    Department of Oncology, Zurich University Hospital, Zurich, Switzerland
    Cancer Biol Ther 5:483-4. 2006
    ..Our data confirm the capacity of gefitinib to accumulate in solid human tumors in vivo...
  12. doi Extraneural spread of glioblastoma--report of two cases
    Arnoud Templeton
    Medizinische Onkologie, Kantonsspital St Gallen, Schweiz
    Onkologie 31:192-4. 2008
    ..2 years after initial diagnosis she presented with a pleural mass which was a metastasis of the formerly diagnosed glioblastoma...
  13. ncbi Metabolic deactivation of low-grade glioma during chemotherapy
    Ulrich Roelcke
    J Neurol 254:668-9. 2007
  14. ncbi Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network
    Damien C Weber
    University Hospital of Geneva, Geneva, Switzerland
    Int J Radiat Oncol Biol Phys 66:179-86. 2006
    ..The aim of this study was to assess the outcome in patients with cerebellar glioblastoma (GBM) treated in 15 institutions of the Rare Cancer Network...
  15. ncbi Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p
    Stefan Kneifel
    Clinic and Institute of Nuclear Medicine, University Hospitals, Basel, Switzerland
    Clin Cancer Res 12:3843-50. 2006
    ..The complex geometry of rapidly proliferating high-grade gliomas requires a diffusible system targeting tumor-associated surface structures to saturate the tumor, including its margins...
  16. ncbi Avoiding glucocorticoid administration in a neurooncological case
    Hans Peter Rutz
    Division of Radiation Medicine, Paul Scherrer Institut, Switzerland
    Cancer Biol Ther 4:1186-9. 2005
    ..The role of COX-2 inhibitors in treatment of GBM is detailed, leading to the conclusion of a pressing need for a clinical evaluation of non-steroidal COX-2 inhibitors with the ability to penetrate into brain tumors...
  17. ncbi Delayed-onset and long-lasting severe neutropenia due to rituximab
    Silvia Hofer
    Department of Medical Oncology, St Claraspital, Basel, Switzerland
    Swiss Med Wkly 134:79-80. 2004
    ..The antibody's toxicity is generally mild and transient. There are reports of protracted neutropenia in patients treated with rituximab...
  18. ncbi Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma
    Silvia Hofer
    Br J Haematol 122:690-1. 2003